BioPharmSignal logoBioPharmSignal

Biotech News

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Liquidia Corporation (LQDA)Liquidia CorporationEarnings

YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026

Related news

LQDALiquidia Corporation2026-07-29 12:30 EST

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

LQDALiquidia Corporation2026-05-11 10:30 EST

Liquidia Corporation Reports First Quarter 2026 Financial Results

View all latest news

Liquidia Corporation

Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved...

Recent company news

LQDALiquidia Corporation2026-08-12 10:30 EST

Liquidia Corporation Reports Second Quarter 2026 Financial Results

LQDALiquidia Corporation2026-07-29 12:30 EST

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

LQDALiquidia Corporation2026-06-11 12:30 EST

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

LQDALiquidia Corporation2026-06-08 12:30 EST

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

LQDALiquidia Corporation2026-05-27 12:30 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

Stock data

Close
77.70 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States